On the other hand, mutations in the Speckle-Type POZ Protein (SPOP) gene were shown to be biomarkers linked to better prognosis and enhanced response to androgen deprivation therapy in de novo metastatic castration-sensitive PC, as the loss of function of SPOP that happens during early prostate tumorigenesis leads to steady AR expression and upregulated AR signaling [59,60,61]. The gene discussed is SPOP; the disease is pachyonychia congenita.